Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-337-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity, rat (OECD Guideline 401): LD50 > 5000 mg/kg bw
Acute dermal toxicity study, rat (OECD Guideline 402): LD50 >2000 mg/kg bw
Acute inhalation toxicity study, rat, nose only (OECD guideline 403): LC50 > 4,14 mg/L
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Dose descriptor:
- LC50
- Value:
- 4 140 mg/m³ air
Acute toxicity: via dermal route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
For the acute oral toxicity 5 similar rat studies are available, all indicating that the LD50 is > 5000 mg/kg body weight. The key study is an acute oral toxicity study of RDP, investigated according to international guidelines (OECD guideline 401, EU Method B.1) under GLP. Five male and five female rats were exposed to a concentration of 5000 mg/kg bodyweight of the test substance (chemical identity and purity not reported). After 14 days no deaths or signs of toxicity were recorded, neither did macroscopic necropsy reveal any results caused by the treatment. The oral LD50 for both male and female rats was determined to be > 5000 mg/kg bodyweight.
In a similar study the acute oral toxicity of the test substance (purity 61.9%) was investigated according to OECD guideline 401. 10 female and 10 male rats were exposed to 5000 mg/kg bodyweight of the test substance by gavage and observed for 14 days. Mortality, clinical signs, Monocyte Non-Specific Esterase Determination, Gross Pathology, Gross necropsy were recorded. The LD50 for both male and female rats was determined to be > 5000 mg/kg bodyweight. MNSE activity was significantly decreased 14 days after dosing in both male and female rats.
In another acute oral study 5 male 5 female rats were exposed to 5000 mg/kg body weight. No treatment-related effects on cholinesterase levels were observed in male rats, whereas in female rats cholinesterase levels were significantly reduced up till 72 hrs after dosing. After 7 days, cholinesterase levels had returned to normal.
The acute dermal toxicity of RDP towards Wistar rats was investigated according to OECD guideline 402 under GLP. Rats were exposed to 2000 mg/kg bodyweight of the test substance for 24 hours and observed for 14 days. The LD50 was determined to be > 2000 mg/kg bodyweight for both males and females.
In another similar dermal study, which is included as a supporting study, MSNE activity was significantly decreased in both males and females fourteen days after dermal exposure of 2000 mg/kg body weight..
The acute inhalation toxicity of Fyrolflex RDP towards rats was investigated according to OECD guideline 403 under GLP. Ten male and ten female rats were exposed to 4.14 mg/L (measured concentration) of the test substance for 4 hours and observed for 14 days. The LC50 was found to be > 4.14 mg/l. MSNE activity was reduced significantly one day after exposure in both males and females, but had returned to normal after 14 days.
A supporting study is available in which the acute inhalation toxicity of CR-733 -S was investigated according to OECD guideline 403 under GLP. Five male and five female rats were exposed to 4.86 mg/l of the test substance for 4 hours and observed for 14 days. The LC50 was found to be > 4.86 mg/l for both male and female rats.
In addition to the studies above, an acute toxicity study via intraperitoneal injection is available which is included as a supporting study. An LD50 >6500 mg/kg bw was observed, which supports the findings in the oral, dermal and inhalation studies that RDP is not acutely toxic.
Justification for classification or non-classification
Based on the available toxicity information RDP has been shown to be not acute toxic when applied via the oral, dermal and inhalation route. Therefore, RDP does not need to be classified for acute toxicity, according to the criteria laid down in Annex VI of the EEC Council Directive 67/548/EEC (amended by Directive 83/467/EEC), and outlined in Annex I of 1272/2008/EC (CLP/EU-GHS).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.